# BPC-157 TB-500 FAQ: Synergy, Safety, Dosing, and Legal Status Questions

> BPC-157 TB-500 FAQ: 25 direct, cited answers on the Wolverine blend — what it is, how the two peptides differ, synergy evidence, side effects, dosing, half-life, and FDA 503A status.

Twenty-five questions on BPC-157 TB-500 — definition, mechanism, evidence, dosing, safety, and access — each answered directly and cited to a study where the answer is quantitative.

## Evidence and the data gap

The state of the evidence on the BPC-157 TB-500 blend, in three questions: what the latest research shows, what reviewers conclude, and whether the combination has been trialed in humans.

## Definition and naming

What the BPC-157 TB-500 blend is, what it contains, and how the two peptides differ.

## What it is studied for

Each repair claim traces to single-compound, mostly animal data — never a combination trial.

## Mechanism and synergy

How each peptide works, and what the synergy claim does and does not rest on.

## Dosing, half-life, and reconstitution

Research-context dosing facts only — no human guidance, no validated blend protocol.

## Side effects and safety considerations

On [side effects and safety considerations](/faq): human safety data are limited to the individual constituents, and one signal warrants explicit framing.

## Regulatory and legal status

Approval, anti-doping, and FDA 503A status — answered from the audited record. Full detail is on [Wolverine legal status and FDA 503A category](/legal-status).

---

Two peptides indexed as one data store — BPC-157 and TB-500 each filed under its own studies and its own 503A status, the synergy entry kept empty because no controlled combination trial exists; an editorial archive, not a clinic, not a vendor, not a prescription.